Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

RELATED NEWS
Trade FRX now with 

Forest Laboratories, Inc. (FRX: Quote) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

Click here to receive FREE breaking news email alerts for Forest Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With traders reacting positively to the results of Scotland's independence referendum, stocks are likely to extend their recent upward move in early trading on Friday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 74 points. Testosterone, often considered as the "fountain of youth", is the major sex hormone in men, and as they age the level of this hormone also naturally declines. The condition in which the body doesn't produce enough testosterone is known as hypogonadism or simply, Low T. European Central Bank Executive Board Member Benoit Coeure and a Germany's Deputy Labor Minister Joerg Asmussen have urged Germany to cut taxes on wages and promote investment to revive the euro area economy. In a jointly-authored opinion piece for the German daily Berliner Zeitung and the French...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.